Mamucan, Loreto P.

HRN: 27-35-53  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/20/2025
CEFTAZIDIME 1GM (VIAL)
06/20/2025
06/26/2025
IV
1g
Q8h
CAP-MR
Pending Pharmacy Acceptance 

 Indication:  Empiric    Type of Infection:  Pneumonia    Compliance to guidelines: